BridgeBio announces first patient dosed in Phase 1 trial of BBP-398 with OPDIVO

BridgeBio Pharma (BBIO) announced that the first patient with non-small cell lung cancer, NSCLC, has been dosed in its Phase 1/2 clinical trial of BBP-398, an investigational SHP2 inhibitor, with Bristol Myers Squibb’s (BMY) OPDIVO in advanced solid tumors with KRAS mutations. "SHP2 has been shown to be a key regulator of both tumor and immune cell signaling. In KRAS mutant tumors, SHP2 promotes survival, proliferation and decreased immunogenicity by driving the active form of KRAS, while in immune cells, it associates with PD-1 which leads to immunosuppression in the tumor microenvironment," said Eli Wallace, Ph.D., chief scientific officer of oncology at BridgeBio. "By partnering with Bristol Myers Squibb on this trial, we hope to show that targeting PD-1 with a two-prong approach can unlock the potent benefits of immunotherapy against this cancer and provide new treatment options for patients who need them."